IMETABOLIC BIOPHARMA

With over 22 years of industry business and research experience, Dr. Urban A. Kiernan is the Founder, Chairman and CEO of iMetabolic Biopharma Corporation (iMBP). Under his leadership iMBP has raised >$1.1 Million in startup investment, established two partnership deals with Ligand Pharmaceuticals/OmniAb, and an additional partnership with Amazon Web Services. These partnerships have paid off with dividends as they have led to the establishment of both the iPlatform™ and a drug asset pipeline towards five different disease programs. Doing more with less is Dr. Kiernan’s business philosophy. Prior to starting iMBP, Dr. Kiernan was the Director of Biomarker Discovery at Intrinsic Bioprobes Inc, during which time he was the recipient of ~$4 Million in Phase I & II National Institutes of Health grants, negotiated significant licensing and service deals with companies such as Johnson & Johnson and Promedior, and was able to achieve his first business exit through acquisition. He then later worked for Thermo Fisher Scientific and was able to quickly rise through the ranks into Global Business Development, providing him a breadth of knowledge and experience in the life science and biopharma sectors. He received his M.Sc. and Ph.D. from Arizona State University, is a devoted husband, father and Jiu Jitsuka. He has authored more than 45 peer reviewed publications, 4 book chapters and received 11 patent awards…and there is still more to come!!!

David Hendren has extensive experience launching, financing, and building successful ventures from incubation to exit, with particular expertise in healthcare, life science, biomedical technology, digital health, and related technology and service areas. He has deep knowledge and broad perspective from 25+ years in leadership roles on virtually all sides of the table, including VC, entrepreneur, CEO, board member/chair, advisor, consultant, and counsel. David has launched successful medical technologies from inception, and led, co-invested and executed deals with leading firms and strategics, with exits including IPO, M&A, and technology licensing transactions cumulatively exceeding $1B. In operating, board, and advisory roles, David has been central to identifying opportunity, building teams, formulating strategy, securing capital, developing business and strategic alliances, and driving successful exits to harvest value for stakeholders. He earned his AB at Dartmouth College and his JD at Northwestern University Pritzker School of Law.

Dr. Munk has over 25 years of experience in the life science and pharmaceutical industry. He currently serves as the Deputy Director of the Biodesign Institute at Arizona State University, but spent the last two decades as the CEO of Ash Stevens Inc, a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization. Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances and received six NIH research contacts. He received his B.S. degree in chemistry at ASU, and then earned his Ph.D. in organic synthesis at The University of California at Berkeley. He is experienced in drug discovery, development, and manufacturing both as a scientist and as a manager.

Jeffrey Zimmerman (Jeff) practiced law for 44 years with emphasis in business and entrepreneurship. He received his undergraduate degree in 1974 from Fort Hays Kansas State University and his Juris Doctor degree from the University of Kansas in 1977. Jeff has served as general counsel to several corporations. He also served as president of several corporations he had a role in founding. He has assisted in the merger or acquisition of several businesses. He currently serves on the board of directors of three for-profit corporations and serves on several not-for-profit charitable and arts boards. Jeff is a graduate of the Kauffman Foundation Center for Entrepreneurial Studies Fast Track Entrepreneurial Training Program. In his practice he has handled numerous multi million dollar business sales and acquisitions and is well versed in all area business finance.